Welcome to this special section on the American Diabetes Association’s 76th Scientific Sessions. Readers may already have noticed the occasional reviews of ADA abstracts in our usual sections. In addition to these, this expanded meeting report covers the most important publications to emerge from the meeting, along with expert commentary on the two headline presentations, LEADER and EMPA-REG OUTCOME, from Mark Kennedy and Rudy Bilous.
A number of the studies reviewed here were published simultaneously at ADA and in major journals. In such cases we have taken care to review the full publications with our usual scoring system in terms of readability, applicability to practice and wow factor. For the shorter meeting abstracts, such ratings were deemed less useful and have been omitted.
In preparing this digest, special thanks are owed to Iain Cranston, Consultant Physician in Diabetes and Endocrinology at Portsmouth Hospitals NHS Trust, for all his work identifying the key studies for the associate editors. This involved sifting through more than 180 hours of presentations, 3000 posters and 20 company symposia! In a climate where clinicians have less time and funding available to attend the major diabetes meetings, the Editors hope readers will find this comprehensive overview useful in keeping them up to date with all the latest developments from both sides of the Atlantic.
Attempts to achieve remission, or at least a substantial improvement in glycaemic control, should be the initial focus at type 2 diabetes diagnosis.
9 May 2024